Between Disorder and Demand

Adult ADHD, Cognitive Overload, and Practicing Psychiatry in the In-Between

Photo by Gianfranco Grenar on Unsplash

Between Disorder and Demand

A few weeks ago, I was speaking with a PMHNP colleague who sounded unusually defeated. She wasn’t talking about patient acuity, staffing shortages, or reimbursement cuts. Instead, she said, almost apologetically, “I think I’m going to leave this practice. Every adult in this county thinks they have ADHD.”

She wasn’t being dismissive. She was exhausted. Every mental health clinician understands exactly what she means.

In the last five years, ADHD evaluations in adults—particularly those in their 20s, 30s, 40s, and 50s—have exploded. Recent stats show that 1 in 4 American adults now think they have the condition. During the pandemic, stimulant prescriptions for adults ages 20-39 rose a whopping 30%. Lawyers, corporate executives, middle level managers, and every other shade of high functioning professional presents with difficulty concentrating, mental fatigue, task paralysis, and a distinct sense that their cognitive bandwidth has narrowed. They are not failing in obvious ways. They are struggling to maintain a level of performance that once felt sustainable. And they all want to know the same thing: Is this ADHD? Or is something else happening?

This is not a fringe phenomenon. Every clinician in primary care and mental health is navigating this tension. Referrals arrive with increasing frequency. Primary care clinicians, appropriately wary of prescribing controlled substances, and therapists, unable to prescribe controlled substances, increasingly defer these nuanced evaluations to psychiatry—often with an implicit expectation that stimulant prescriptions will follow. Meanwhile, mental health clinicians are left holding the diagnostic hot potato, along with the full ethical and regulatory weight that comes with it.

The uncomfortable truth is that the line between executive dysfunction and cognitive performance enhancement has never been blurrier. Where is the starting line? Are we treating true impairment or fine tuning already functional brains to compete in an increasingly frenetic world?

ADHD is a neurodevelopmental disorder. Its core features—impulsivity, inattention, executive dysfunction—do not suddenly emerge in midlife, or with the presence of added scholastic or professional stress. And yet, many adults now describe lifelong patterns that were either masked by structure, compensated for by intelligence, or rendered invisible in environments that demanded less sustained cognitive output. Some of these individuals meet criteria. Some do not.

What has clearly changed is the cognitive environment. The average adult in America in 2026 is operating under relentless information load: constant digital interruptions, collapsing boundaries between work and rest, productivity metrics that reward speed over depth, and chronic sleep deprivation. Under these conditions, even intact executive functioning degrades. The result looks a lot like ADHD—but may be something closer to cognitive overload.

This distinction matters because the treatment implications are profound.

Stimulants are highly effective medications—for ADHD. But they also function as mental amplifiers. They increase focus, task persistence, and cognitive endurance even in individuals without a neurodevelopmental disorder. When I was in college, binge studying with Adderall was so common it was nicknamed “vitamin A.” The week before finals, a slew of inquiries would pop up on the student list serve with headlines like “seeking vitamin A” and “vitamin deficient this week. Will pay for A.” Later as a psychiatrist, one college student patient admitted to paying for their off-campus student housing by selling “vitamin A” to fellow students. Recent studies show that up to 62% of college students prescribed ADHD medication admit to sharing it or selling it, often for academic enhancement.

The analogy that comes to mind is elite sports. Doping is not enticing because athletes are underperforming. It is tempting because they are already performing at a high level—and the margins for maintaining that performance keep shrinking. Adding a substance becomes a way to sustain excellence in an environment that demands more than biology was designed to give.

This creates an ethical gray zone that psychiatry has not fully reckoned with.

When a high-functioning adult asks for stimulants, the question is rarely, “Am I impaired?” It is more often, “Can I keep up?”

This puts prescribers in a difficult position. On one hand, denying treatment to someone who genuinely has ADHD perpetuates unnecessary suffering. On the other, normalizing pharmacologic enhancement risks medicalizing structural problems—burnout, overwork, digital saturation—while shifting the burden onto individual brains rather than systems.

Unsurprisingly, many clinicians are opting out. Fewer providers are willing to prescribe controlled substances at all. Primary care increasingly “turfs” ADHD to psychiatry. Mental health prescribers inherit not just diagnostic complexity but heightened regulatory scrutiny and moral distress.

The result is a growing sense of professional unease. We are being asked to decide where pathology ends and adaptation begins—often in patients who are intelligent, accomplished, and profoundly depleted.

There is no clean resolution to this tension. But pretending it doesn’t exist helps no one.

As mental health providers, we must hold two truths at once: adult ADHD is real and underdiagnosed—and not every attention problem in 2026 is a disorder. Our role is not to function as gatekeepers of productivity, nor as moral arbiters of enhancement. No. In a world that rewards provider speed and patient satisfaction scores over comprehensive care, our task is something quieter and harder.

Our job is to Slow. Things. Down.

To hold the line. To pause when the world demands acceleration. To zig when everyone else zags. To apply the break when the system keeps flooring the gas. To practice careful diagnosis, honest formulation, transparent conversation, and ethical prescribing in a culture that celebrates mental sprinting and quietly punishes endurance.

If this feels uncomfortable, it should. The discomfort is not a sign of failure. It is evidence that we are practicing at the edge of medicine, culture, and ethics—where the hardest questions of all rarely come with algorithmic answers.

Working in mental health is hard. It’s hard in ways that don’t show up on RVU spreadsheets or quality dashboards. But it is also deeply, stubbornly rewarding.

There is meaning in sitting with uncertainty, in refusing to simplify human suffering into checkbox diagnoses, EMR dropdowns, patient reported questionnaires, and CPT codes.

This work lives in uncertainty—diagnostic, ethical, and moral—and that is what makes it both exhausting and quietly extraordinary. There are no algorithms for deciding where illness ends and adaptation begins, no metrics for the weight of a careful “not yet,” and no applause for clinicians who choose nuance over speed. Yet every day, providers show up anyway. They sit with ambiguity, tolerate dissatisfaction (their own and others’), and make decisions knowing they may be misunderstood by patients, administrators, or regulators alike. That willingness—to practice thoughtfully in the absence of certainty—is not a weakness of the field. It is one of its deepest strengths.

-Lauren Grawert

TAGS: #laurengrawert #advancedpracticepartners #wisconsin #mentalwellness #2025 #2026 #health #oped #wisdom #hipaa #psychiatrists #pmhnp #therapists #psychology #medical

LINKS: advancedpracticepartners.com | The White Coat Warrior  | WIKI LINKEDIN | Lauren Grawert | Robert Glenn | Jon Snipes

© 2026